Notably, updated data from KEYNOTE‐224 showed median DoR to anti‐PD1 therapy in advanced HCC was 21.0 months (range 3.1−39.5+ months),32 highlighting acquired resistance as a significant impediment to the long‐term survival of PD1 blockade‐sensitive patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.